CXCR4 is overexpressed in more than 23 different types of cancers, including breast, pancreatic, and lung cancers. The interaction between CXCR4 and CXCL12 promotes tumor growth, metastasis, angiogenesis, and survival. This makes CXCR4 a compelling target for cancer therapy.
